Lipid Levels and Renal Function Decline in Pre-Dialysis Patients

Moniek C.M. de Goeij\textsuperscript{a} Joris I. Rotmans\textsuperscript{b} Xanthe Matthijssen\textsuperscript{a} Dinanda J. de Jager\textsuperscript{a} Friedo W. Dekker\textsuperscript{a} Nynke Halbesma\textsuperscript{a, c} for the PREPARE-2 Study Group

Departments of \textsuperscript{a}Clinical Epidemiology and \textsuperscript{b}Nephrology, Leiden University Medical Center, Leiden, The Netherlands; \textsuperscript{c}Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK

Key Words
CKD stages IV–V · Pre-dialysis care · Lipids · Renal function decline · Statin · Fibrate

Abstract

\textbf{Background:} Little is known about the effect of low-density lipoprotein (LDL) cholesterol, triglyceride (TG), and high-density lipoprotein (HDL) cholesterol levels on renal function decline in patients receiving specialized pre-dialysis care. \textbf{Methods:} In the prospective PREPARE-2 study, incident patients starting pre-dialysis care were included when referred to one of the 25 participating Dutch specialized pre-dialysis outpatient clinics (2004–2011). Clinical and laboratory data were collected every 6 months. A linear mixed model was used to compare renal function decline between patients with LDL cholesterol, TG, or HDL cholesterol levels above and below the target goals (LDL cholesterol: <2.50 mmol/l, TG: <2.25 mmol/l, and HDL cholesterol: \geq 1.00 mmol/l). Additionally the HDL/LDL cholesterol ratio was investigated (\geq 0.4). \textbf{Results:} In our study population (n = 306), the median age was 69 years and 70\% were male. Patients with LDL cholesterol levels above the target of 2.50 mmol/l experienced an accelerated renal function decline compared to patients with levels below the target (crude additional decline: 0.10 ml/min/1.73 m\textsuperscript{2}/month, 95\% CI 0.00–0.20; p < 0.05). A similar trend was found for TG levels above the target of 2.25 mmol/l (0.05 ml/min/1.73 m\textsuperscript{2}/month, 95\% CI –0.06 to 0.16) and for a HDL/LDL cholesterol ratio below 0.4 (0.06 ml/min/1.73 m\textsuperscript{2}/month, 95\% CI –0.05 to 0.18). Adjustment for potential confounders resulted in similar results, and the exclusion of patients who were prescribed lipid-lowering medication (statin, fibrate, or cholesterol absorption inhibitor) resulted in a slightly larger estimated effect. \textbf{Conclusion:} High levels of LDL cholesterol were associated with an accelerated renal function decline, independent of the prescription of lipid-lowering medication.
Introduction

In the general population, it is known that abnormal lipid levels, i.e. high low-density lipoprotein (LDL) cholesterol, high triglycerides (TG), and low high-density lipoprotein (HDL) cholesterol levels, are associated with higher cardiovascular mortality [1–3]. For patients on dialysis treatment, the association of abnormal lipid levels with all-cause and cardiovascular mortality is different compared with the general population. Having abnormal lipid levels (especially high total cholesterol) seems to have a beneficial effect in these patients, associated with lower risks of mortality [4–6]. Studies investigating the association of abnormal lipid levels with all-cause and cardiovascular mortality in chronic kidney disease (CKD) patients not on dialysis [7–9] showed no or a slightly reversed association. However, this reversed association was again mainly observed for total cholesterol levels, which is a combination of ‘good’ and ‘bad’ lipids. Moreover, low cholesterol levels may be a consequence of inflammatory processes [10, 11]. Besides this, a subgroup analysis of a large trial showed that a lipid-lowering combination therapy of a statin plus cholesterol absorption inhibitor, both LDL cholesterol-lowering medications, decreased the risk of major cardiovascular events (including cardiovascular mortality) in pre-dialysis patients [12]. Primarily based on the results from this trial, lipid-lowering medication is recommended to pre-dialysis patients for preventing cardiovascular complications. Is there also enough evidence available for renal function decline, another important clinical outcome?

In the general population, several studies found a possible association of abnormal lipid levels with an accelerated renal function decline [13–16]. This association seems comparable in patients with CKD, in whom abnormal lipid levels are associated with a faster disease progression [17–21]. However, these studies mainly focused on total cholesterol levels in early-stage CKD patients (stages I–III). Data are lacking on the association of high LDL cholesterol, high TG, and low HDL cholesterol levels with the progression of CKD in pre-dialysis patients (stages IV–V). Furthermore, trials investigating the effect of statins on disease progression, either defined by increasing proteinuria levels or renal function decline, are scarce and show contradictory results in pre-dialysis patients [12, 22]. Therefore, we investigated the association of abnormal lipid levels (high LDL cholesterol, high TG, and low HDL cholesterol) with renal function decline in incident patients receiving specialized pre-dialysis care (CKD stages IV–V).

Methods

Study Design

The PREdialysis Patien REcord-2 (PREPARE-2) study is a prospective follow-up study of incident pre-dialysis patients treated in one of the 25 participating nephrology outpatient clinics in the Netherlands. Patients were included between July 2004 and June 2011 at the start of specialized pre-dialysis care. They were treated by their nephrologists in their regular scheme according to the treatment guidelines of the Dutch Federation of Nephrology [23], guidelines partly based on the K/DOQI and KDIGO guidelines [24, 25]. At the start of specialized pre-dialysis care and in subsequent 6-month intervals, clinical data were collected. Patients were followed until the start of dialysis, receiving a kidney transplant, death, or censoring. Censoring was defined as: moving to an outpatient clinic not participating in the PREPARE-2 study, recovery of kidney function, refusal of further study participation, loss to follow-up, or August 1, 2012 (end of follow-up), whichever came first. The study was approved by the Medical Ethics Committee or Institutional Review Board (as appropriate) of all participating centres.
Patients

To be eligible for inclusion in the PREPARE-2 study, patients had to be at least 18 years of age. If possible, the inclusion should take place at the moment of referral to a specialized pre-dialysis outpatient clinic. In practice, this refers to incident pre-dialysis patients with an estimated glomerular filtration rate (eGFR) of <20–30 ml/min/1.73 m², in whom renal function loss is progressive. Patients with a failing kidney transplant were also included in the study if the transplantation had taken place at least 1 year ago. All participants gave their written informed consent prior to study inclusion.

Data Collection

Data on demography, biometry, primary kidney disease, co-morbidities, medication use, and health-related quality of life were collected at the start of specialized pre-dialysis care and in subsequent 6-month intervals. Corresponding laboratory data were extracted from the electronic hospital information systems or medical records. Primary kidney disease was classified according to the codes of the European Renal Association-European Dialysis and Transplantation Association [26].

Measurements and Definitions

GFR was estimated using the 4-variable Modification of Diet in Renal Disease (MDRD) formula [27]. TG and HDL cholesterol levels (given in mmol/l) were directly measured according to the standard procedure in each participating outpatient clinic. LDL cholesterol (given in mmol/l) was either directly measured or estimated with the Friedewald equation: total cholesterol – HDL cholesterol – TG/2.2 [28].

Outcome

The primary outcome of our study was renal function decline. For the calculation of this decline, all individual eGFR measurements during the first 2 years of pre-dialysis care were used. Complete follow-up data were not used because the healthy and stable patients, who are still on pre-dialysis care after 2 years, would then provide a relatively large contribution to the overall renal function decline, possibly leading to a dilution of the estimated decline.

Statistical Analyses

For our statistical analyses, we only included those patients with at least one LDL cholesterol, TG, HDL cholesterol, and eGFR measurement during the first 2 years of pre-dialysis care (n = 306). Baseline characteristics were presented as mean ± SD for normally distributed continuous variables and as median (boundaries of interquartile range, IQR) for skewed continuous variables. LDL cholesterol, TG, and HDL cholesterol levels were used as determinants. All determinants were analyzed in categories based on the target goals recommended by the Dutch [23] and international [24, 29] pre-dialysis guidelines. The targets were <2.50 mmol/l for LDL cholesterol, <2.25 mmol/l for TG, and ≥1.00 mmol/l for HDL cholesterol. Two additional analyses were performed: (1) HDL cholesterol relative to LDL cholesterol (HDL/LDL cholesterol ratio: 1/2.50 mmol/l = 0.4; target ≥0.4) because HDL levels can be influenced by LDL levels, and (2) the number of targets that are not reached (1; not reaching 1 of the targets, 2; not reaching 2 of the targets, and 3; reaching none of the targets) to estimate the combined effect of lipid levels.

To associate these lipid levels with renal function decline, we used a linear mixed model. This model takes into account a correlation between individual repeated eGFR measurements and the deviation of the individual slopes from the mean slope [30]. All lipid levels and eGFR measurements during the first 2 years of pre-dialysis care were included in the model. The covariates included in the model were time (random), lipid levels, and time × lipid levels.
(interaction term; to assess the difference in renal function decline between the lipid level categories). All analyses were adjusted for the potential baseline confounders age, sex, primary kidney disease, smoking status, cardiovascular disease, diabetes mellitus, body mass index, systolic blood pressure, and proteinuria. In an additional model, we further adjusted for available malnutrition-inflammation complex system-related factors (albumin, C-reactive protein, and subjective global assessment). To maintain power and avoid bias, missing baseline confounder values were imputed (using 10 repetitions) with the method of multiple imputations in PASW/SPSS version 20.0. This is a recommended technique where missing data for a patient are imputed by a value that is predicted by other known characteristics of this patient [31, 32]. All characteristics in tables 1 and 2, follow-up time, and the outcome (dialysis, transplantation, death, or censoring) were included in the imputation model, because missing baseline characteristics are often related to the outcome [33]. For each baseline characteristic, the number of patients with an available value is given in tables 1 and 2. Skewed distributed continuous variables, including follow-up time, were logarithmically transformed before being entered into the model.

We performed several additional analyses. First, we excluded patients who were prescribed lipid-lowering medication, defined as either a statin, a fibrate, or a cholesterol absorption inhibitor. Second, we analyzed the abnormal lipid levels continuously to investigate whether there was a similar association throughout the entire range of lipid levels. Third, we compared the effect of LDL cholesterol levels on renal function decline between the centres who estimated LDL cholesterol levels with the Friedewald equation and the centres who directly measured LDL cholesterol. Fourth, we excluded eGFR values measured in the 2 weeks before starting dialysis, receiving a kidney transplant, death, or censoring, because

<table>
<thead>
<tr>
<th>Table 1. Baseline patient characteristics for the total population and stratified by the LDL cholesterol target goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (n = 306)</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>below the target (n = 100)</td>
</tr>
<tr>
<td>Age, years</td>
</tr>
<tr>
<td>Male, %</td>
</tr>
<tr>
<td>Smokers/quitters &lt;1 year before inclusion, %</td>
</tr>
<tr>
<td>Primary kidney disease, %</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
</tr>
<tr>
<td>Renal vascular disease</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>eGFRb (n = 286), ml/min/1.73 m²</td>
</tr>
<tr>
<td>Proteinuria (n = 178), g/24 h</td>
</tr>
<tr>
<td>Systolic blood pressure (n = 304), mm Hg</td>
</tr>
<tr>
<td>Hemoglobin (n = 288), g/dl</td>
</tr>
<tr>
<td>Cardiovascular diseasec, %</td>
</tr>
<tr>
<td>Diabetes mellitusd, %</td>
</tr>
</tbody>
</table>

Values are given as medians (boundaries of IQR) for age and proteinuria and as means ± SD for all other normally distributed continuous variables.

a Before multiple imputation, LDL cholesterol levels were available for 197 patients. b eGFR is calculated with the 4-variable MDRD formula. c Defined as the presence of a cerebrovascular accident, vascular problems, angina pectoris, myocardial infarction, or decompensatio cordis. d Present as primary kidney disease or co-morbidity.
there can be a large variation between eGFR measurements during this period. Fifth, we repeated all analyses after excluding the patients with only one eGFR measurement, to check whether the results from our linear mixed model were robust. Finally, we stratified our results by sex, because female hormones could influence the association between lipid levels and renal function decline [34]. p values <0.05 were considered statistically significant. Data were analyzed with PASW/SPSS version 20.0.

Results

Baseline Characteristics

Of the 502 patients, 306 patients had at least one LDL cholesterol, TG, HDL cholesterol, and eGFR measurement during the first 2 years of follow-up. These 306 patients were included in our statistical analyses and the known baseline characteristics of these patients (table 1) were very similar to the baseline characteristics of the 196 patients excluded. The median age of the population was 69 years (IQR 56–76) and 70% were male. Mean eGFR ± SD was 16.7 ± 6.1 ml/min/1.73 m² and median proteinuria was 1.1 g/24 h (IQR 0.3–2.2). Stratification by the LDL cholesterol target goal (<2.50 mmol/l) revealed that patients above the target were slightly younger, less often male, had a slightly higher eGFR, higher systolic blood pressure, and had less often diabetes mellitus and cardiovascular disease (as primary kidney disease or co-morbidity) than patients below the target.

At the start of pre-dialysis care, 17% of the patients were treated with lipid-lowering medication (including statins, fibrates, and cholesterol absorption inhibitors; table 2). Of the patients with LDL cholesterol levels above the target goal (≥2.50 mmol/l), only 19% were prescribed lipid-lowering medication. For patients with TG levels above the target goal (≥2.25 mmol/l), this percentage was 23%. After 6 months of follow-up, these percentages...
slightly increased to 21 and 26%, respectively. After stratification by the LDL cholesterol target goal (<2.50 mmol/l), malnutrition/inflammation markers – such as serum albumin and C-reactive protein – were similar between patients below and above the target.

Renal Function Decline

The overall renal function decline for all 306 patients was 0.19 ml/min/1.73 m²/month (95% CI 0.14–0.23). The median number of eGFR measurements during the first 2 years of follow-up was 3 (IQR 2–4) and 8, 33 and 59% of these patients had 1, 2 and ≥3 measurements, respectively. Patients with LDL cholesterol levels above the target goal of 2.50 mmol/l experienced an additional renal function decline (crude: 0.10 ml/min/1.73 m²/month, 95% CI 0.00–0.20; p < 0.05) compared to patients with levels below the target.

### Table 3. Association of lipid levels with renal function decline

<table>
<thead>
<tr>
<th>Measurements, %</th>
<th>Additional renal function decline (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>crude</td>
</tr>
<tr>
<td><strong>LDL cholesterol, mmol/l</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;2.50</td>
<td>ref</td>
</tr>
<tr>
<td>≥2.50</td>
<td>0.10 (0.00 to 0.20)*</td>
</tr>
<tr>
<td><strong>TG, mmol/l</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;2.25</td>
<td>ref</td>
</tr>
<tr>
<td>≥2.25</td>
<td>0.05 (–0.06 to 0.16)</td>
</tr>
<tr>
<td><strong>HDL cholesterol, mmol/l</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;1.00</td>
<td>ref</td>
</tr>
<tr>
<td>≥1.00</td>
<td>–0.06 (–0.17 to 0.04)</td>
</tr>
<tr>
<td><strong>HDL/LDL cholesterol ratio</strong></td>
<td></td>
</tr>
<tr>
<td>&lt;0.40</td>
<td>ref</td>
</tr>
<tr>
<td>≥0.40</td>
<td>0.06 (–0.05 to 0.18)</td>
</tr>
<tr>
<td><strong>Targets not reached</strong></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>ref</td>
</tr>
<tr>
<td>2</td>
<td>0.03 (–0.19 to 0.13)</td>
</tr>
<tr>
<td>3</td>
<td>0.04 (–0.15 to 0.22)</td>
</tr>
</tbody>
</table>

The additional decline in renal function with its 95% CI is given for the lipid level category not reaching the recommended target goal (LDL cholesterol ≥2.50 mmol/l, TG ≥2.25 mmol/l, and HDL cholesterol <1.00 mmol/l) compared to the reference category (reaching the recommended target goal). The decline was assessed with a linear mixed model. A positive number indicates an additional decline in renal function.

* Including the targets for LDL cholesterol, TG, and the HDL/LDL cholesterol ratio, excluding patients reaching all targets. \(^{\dagger}\) The crude mean (95% CI) renal function decline in patients reaching the recommended target goals was 0.11 ml/min/1.73 m²/month (0.04–0.18) for LDL cholesterol, 0.15 ml/min/1.73 m²/month (0.09–0.22) for TG, 0.17 ml/min/1.73 m²/month (0.11–0.24) for HDL cholesterol, 0.14 ml/min/1.73 m²/month (0.07 to 0.20) for the HDL/LDL cholesterol ratio, and 0.16 ml/min/1.73 m²/month (0.06–0.26) for reaching only 1 of the targets. \(^{\ddagger}\) Model 1: adjusted for sex and age; Model 2: additionally adjusted for primary kidney disease, smoking, cardiovascular disease, diabetes mellitus, body mass index, systolic blood pressure, and proteinuria; Model 3: additionally adjusted for albumin, C-reactive protein, and subjective global assessment. * p < 0.05.

Renal Function Decline

The overall renal function decline for all 306 patients was 0.19 ml/min/1.73 m²/month (95% CI 0.14–0.23). The median number of eGFR measurements during the first 2 years of follow-up was 3 (IQR 2–4) and 8, 33 and 59% of these patients had 1, 2 and ≥3 measurements, respectively. Patients with LDL cholesterol levels above the target goal of 2.50 mmol/l experienced an additional renal function decline (crude: 0.10 ml/min/1.73 m²/month, 95% CI 0.00–0.20; p < 0.05) compared to patients with levels below the target (mean decline: 0.11 ml/min/1.73 m²/month, table 3 and fig. 1a). A similar trend (crude: 0.05 ml/min/1.73 m²/month, 95% CI –0.06 to 0.16) was found for patients with TG levels above the target goal of 2.25 mmol/l (mean decline: 0.15 ml/min/1.73 m²/month in patients with levels below the target; table 3 and fig. 1b). For HDL cholesterol levels, the association was reversed (not significant), meaning that patients with HDL cholesterol levels below the target goal of 1.00 mmol/l experienced a slower renal function decline (crude: –0.06 ml/min/1.73 m²/month, table 3 and fig. 1b).
95% CI –0.17 to 0.04) compared to patients with levels above the target (mean decline: 0.17 ml/min/1.73 m²/month, table 3 and fig. 1c). However, when we analyzed HDL cholesterol levels as a ratio of LDL cholesterol levels (1.00/2.50 mmol/l = 0.4), we again found a trend towards a faster renal function decline in patients with a ratio <0.4 (crude: 0.06 ml/min/1.73 m²/month, 95% CI –0.05 to 0.18) compared to patients with a ratio ≥0.4 (mean decline: 0.14 ml/min/1.73 m²/month; table 3 and fig. 1d). Adjustment for potential confounders did not change the results substantially (table 3). Analyzing the number of targets not reached (including LDL cholesterol, TG, and HDL/LDL cholesterol ratio, range: 1–3) showed no additional decline when 2 or 3 targets, instead of only 1 target, were not reached.

Additional Analyses

LDL cholesterol levels above the target goal of 2.50 mmol/l remained associated with an accelerated renal function decline after excluding patients who were prescribed lipid-lowering medication at any moment during follow-up (n = 224 included in the analysis, additional decline: 0.14 ml/min/1.73 m²/month, 95% CI 0.03–0.24, Model 3 adjusted). The association of LDL cholesterol levels with renal function decline was comparable between
patients included from centres that estimated (n = 91) and those that directly measured (n = 215) LDL cholesterol (additional decline: 0.12 ml/min/1.73 m²/month, 95% CI –0.04 to 0.27, Model 3 adjusted, and additional decline: 0.07 ml/min/1.73 m²/month, 95% CI –0.05 to 0.19, Model 3 adjusted, respectively). Analyzing LDL cholesterol levels continuously resulted in an adjusted additional renal function decline of 0.06 ml/min/1.73 m²/month (95% CI 0.01–0.11, Model 3 adjusted) per each 1 mmol/l increase. For TG levels and the HDL/LDL cholesterol ratio, the trend remained present but did not reach statistical significance. Excluding eGFR values measured in the 2 weeks before reaching an endpoint (starting dialysis, receiving a kidney transplant, death, or censoring) or excluding patients with only one eGFR measurement (n = 281 included in the analysis) resulted in very similar results. In men and women, associations of LDL and HDL cholesterol levels with renal function decline were in the same direction, but they were only significant in women.

Discussion

In our cohort of incident patients receiving pre-dialysis care, an accelerated renal function decline was present in patients with LDL cholesterol levels above compared to those with levels below the target goal (<2.50 mmol/l), independent of the prescription of lipid-lowering medication. For TG levels above the target goal (≥2.25 mmol/l) and a HDL/LDL cholesterol ratio <0.4, a trend was present, which did not reach statistical significance. Furthermore, at the start of pre-dialysis care, lipid-lowering medication was only prescribed to 19% of the patients with LDL cholesterol levels above the target goal and 23% of the patients with TG levels above the target goal.

Our observation that abnormal lipid levels were associated with an accelerated renal function decline is in line with studies performed in patients with early to moderate stages of CKD (stages I–IV) [17–21]. Moreover, we found that especially high LDL cholesterol levels were associated with an accelerated renal function decline. Our results may therefore suggest that statins (possibly combined with cholesterol absorption inhibitors), which mainly lower LDL cholesterol levels, are potentially effective medications to slow down renal function decline. However, statin trials have shown contradictory effects on renal function decline in pre-dialysis patients [22, 35, 36]. We have to keep in mind that these trials rarely included patients with advanced stages of CKD (IV–V). Only in the SHARP trial [12], more than half of the included pre-dialysis patients had CKD stages IV–V (3,786 out of 6,247). This trial showed no statistical effect on the combined endpoint of reaching end-stage renal disease, defined as starting dialysis or receiving a kidney transplant, or the doubling of serum creatinine. However, the effect was strongest on doubling of serum creatinine (risk ratio 0.93, 95% CI 0.86–1.01), which mostly resembles our outcome measure of renal function decline. Unfortunately, our study was underpowered to investigate the course of renal function decline in patients who were prescribed lipid-lowering medication (n = 52).

Furthermore, we found a low percentage of patients who were prescribed lipid-lowering medication (17%), which is in line with other studies performed in pre-dialysis patients [37] and in patients receiving hemodialysis [38]. In addition, a striking finding in our cohort is that only 19% of the patients with LDL cholesterol levels above the target goal (≥2.50 mmol/l) and 23% of the patients with TG levels above the target goal (≥2.25 mmol/l) were actually prescribed lipid-lowering medication at baseline. These percentages increased to 21 and 26%, respectively, after 6 months of pre-dialysis care, but were still quite low. These findings are in line with the study by Mason et al. [38], showing that only 20.8% of the patients on hemodialysis with a total cholesterol level ≥5.17 mmol/l, which resembles patients with LDL cholesterol and/or TG levels above the target goal, were actually treated with statins. An
explanation for this low percentage in patients receiving pre-dialysis care and dialysis treatment could be that physicians are not convinced that the prescription of lipid-lowering medication is beneficial in these patients. For example, it may have been unclear for physicians whether patients with abnormal lipid levels, but without an additional cardiovascular risk factor (e.g. a history of diabetes mellitus or cardiovascular disease), should be treated with lipid-lowering medication. Our findings indeed showed a low prevalence of these co-morbidities in patients with LDL cholesterol levels above the target goal of 2.50 mmol/l. On the other hand, a subgroup analysis in the SHARP trial suggests that lipid-lowering medication is beneficial for patients without diabetes mellitus or cardiovascular disease, leading to less major cardiovascular events (composite endpoint: non-fatal myocardial infarction or any cardiac death, any stroke, or any arterial revascularization excluding dialysis access procedures). This evidence may have convinced physicians to prescribe lipid-lowering medication to these patients. However, the effect of lipid-lowering medication on renal function decline has not been elucidated yet. More trials in pre-dialysis patients that investigate this effect are needed but may not be justified to perform. The effect of lipid-lowering medication on the reduction of major cardiovascular events in pre-dialysis patients (CKD stages IV–V) is apparent and this evidence may be sufficient for prescribing these medications to these patients. Therefore, post-hoc subgroup analyses of published trials, meta-analyses and new prospective follow-up data should gain more information about the possible renoprotective effect of lipid-lowering medication.

The great strength of our study lies in its longitudinal character and the inclusion of incident patients. In this way, we could take into account lipid level variability and changes during pre-dialysis care. Furthermore, we could assess renal function decline, which is a more detailed outcome measure compared to the robust measures used in for example the SHARP trial (starting end-stage renal disease or doubling of serum creatinine). A disadvantage of our study is the presence of missing data. Lipid levels were not routinely measured at each pre-dialysis care visit. These missing data resulted in the exclusion of 39% of the patients (196 out of 502). Fortunately, baseline characteristics were very similar between the 306 patients included and the 196 patients excluded from our statistical analyses. Therefore, we could reasonably assume that the exclusion of patients with missing lipid levels did not bias our results. The last thing we have to keep in mind is that our study only included patients with an eGFR <20–30 ml/min/1.73 m² who had been referred to one of our outpatient clinics for pre-dialysis care. Therefore, our results are not generalizable to all patients with CKD stages IV–V.

In conclusion, high levels of LDL cholesterol are associated with an accelerated renal function decline. Further research in the specific population of pre-dialysis patients is necessary to investigate whether lipid-lowering medication can slow down renal function decline.

Acknowledgements

The authors especially thank all patients who participated in the PREPARE-2 study. The nursing staffs of the participating centres as well as the trial nurses and data managers from the Hans Mak Institute are gratefully acknowledged for collecting the clinical data. This study was supported by grants from the Dutch Kidney Foundation (SB 110) and an unrestricted grant from Amgen B.V.
Disclosure Statement

The authors have no involvements that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated. None of the sponsors were involved in the study design, collection of data, statistical analyses, interpretation of data, writing of the manuscript, or in the decision to submit the paper for publication. The results presented in this paper have not been published previously in whole or part, except in abstract format.

References


